胸主动脉腔内修复术治疗主动脉食管瘘的系统综述
该系统综述检索PubMed/MEDLINE和EMBASE至2023年6月,纳入106篇报告共163例主动脉食管瘘患者,评估胸主动脉腔内修复术(TEVAR)的疗效。结果显示总体30天死亡率为11.7%,单纯TEVAR组为18.8%,TEVAR联合分期手术组为4.8%(p=0.006);总体6个月死亡率为34.4%,单纯TEVAR组为48.8%,联合手术组为20.5%(p<0.001)。作者认为TEVAR可急诊用于控制出血,但单纯TEVAR非根治性,条件允许时推荐TEVAR后行手术修复。
要点
- 主动脉食管瘘最常见病因为胸主动脉瘤(34.4%),其次为食管癌(25.2%)。
- 总体30天死亡率为11.7%,单纯TEVAR组18.8% vs 联合分期手术组4.8%(p=0.006)。
- 总体6个月死亡率为34.4%,单纯TEVAR组48.8% vs 联合分期手术组20.5%(p<0.001)。
核心结论
- 主动脉食管瘘时,TEVAR可急诊用于控制出血和血流动力学管理。
- 单纯TEVAR有价值但非根治性手段;TEVAR后行手术修复可能提供更好的结局,条件允许时应推荐。
研究设计与样本
- 系统综述,检索PubMed/MEDLINE和EMBASE至2023年6月。
- 纳入1997年至2023年间发表的106篇报告(92篇病例报告,14篇病例系列),共163例患者(平均年龄58.9±16.5岁)。
主要发现
- 胸主动脉瘤为最常见病因(34.4%),其次为食管癌(25.2%)、食管异物(13.5%)和TEVAR术后并发症(9.8%)。
- 原发性主动脉食管瘘129例(79.1%),继发性34例(20.9%)。
- 单纯TEVAR施行80次(49.1%),TEVAR联合分期食管或主动脉手术施行83次(50.9%)。
- 总体30天死亡率为11.7%(n=19):单纯TEVAR组18.8% vs 联合分期手术组4.8%(p=0.006)。
- 总体6个月死亡率为34.4%(n=56):单纯TEVAR组48.8% vs 联合分期手术组20.5%(p<0.001);平均随访时间12.3±14.7个月,主要死因为主动脉食管瘘复发导致的出血和脓毒症。
临床怎么用
- 作者认为,主动脉食管瘘时TEVAR可急诊施行以控制出血和血流动力学。
- 作者认为单纯TEVAR有价值但非根治性,TEVAR后行手术修复可能提供更好结局,条件允许时应推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Aorto-esophageal fistula (AEF) is a rare condition consisting in a fistula between the aorta and the esophagus. The thoracic endovascular aortic repair (TEVAR) has become an accepted treatment for initial AEF management, but large series are not available and outcomes are questionable. This study aims at evaluating the current evidence of TEVAR in AEF. METHODS: A search on PubMed/MEDLINE and EMBASE was conducted up to June 2023. Data on article type, patients' demographics, cause and type of AEF, clinical presentation, time from clinical presentation to TEVAR, strategies, mortality, and follow-up were analyzed. RESULTS: 106 reports published between 1997 and 2023 were deemed eligible for this study (92 case reports; 14 case-series). A total of 163 patients (mean age: 58.9±16.5 years), diagnosed with AEF and treated with TEVAR (with or without staged surgical repair of the esophagus or the aorta) were included. A thoracic aortic aneurysm (34.4%) was the most common cause of AEF, followed by esophageal cancer (25.2%), foreign body in esophagus (13.5%) and post-TEVAR complication (9.8%). Primary AEF were 129 (79.1%), and secondary AEF were 34 (20.9%). TEVAR alone was performed 80 times (49.1%), while TEVAR with staged esophageal or aortic surgery 83 times (50.9%). The overall 30-day mortality was 11.7% (n=19): 18.8% in TEVAR alone and 4.8% in TEVAR with staged surgery, respectively (p=0.006). Mean follow-up time was 12.3±14.7 months. The overall 6-month mortality was 34.4% (n=56): 48.8% in TEVAR alone and 20.5% in TEVAR with staged surgery (p<0.001). Bleeding for recurrence of AEF and sepsis were the main causes of death. CONCLUSIONS: In case of AEF, TEVAR can be urgently performed for bleeding management and hemodynamic control. TEVAR alone is a valuable yet not definitive procedure. Instead, TEVAR followed by surgical repair may provide better outcomes and should be recommended, when possible.Clinical ImpactThis review summarizes the published papers on endovascular aortic repair for the treatment of aorto-esophageal fistulae. The clinicians can find several important details on how to manage the presence of an esophageal fistulae wich represents a potential life-threatening problem for the patients. The implantation of a thoracic endovascular aortic prosthesis represents a fast and reliable procedure in case of emergency but a second step surgical repair provides better outcomes and should be recommended in suitable patients.
引用
- Wang C, Xi Z, von Segesser LK, et al. Thoracic Endovascular Aortic Repair For The Management of Aorto-Esophageal Fistulae: A Systematic Review. J Endovasc Ther. 2024. PMID: 39564913. doi:10.1177/15266028241300403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。